Pre-made Drozitumab benchmark antibody ( Whole mAb, anti-TNFRSF10B/TRAIL-R2 therapeutic antibody, Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-156

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-156 Category Tag

Product Details

Pre-Made Drozitumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Drozitumab is a human monoclonal antibody in development for the treatment of cancers.[1] It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.[2] Drozitumab was developed by Genentech.

Products Name (INN Index)

Pre-Made Drozitumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody

INN Name

Drozitumab

Target

TNFRSF10B

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Lambda

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Discontinued

100% SI Structure

4od2:BA

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2010

Companies

Genentech

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Chondrosarcoma,Colorectal cancer,Non-Hodgkin's lymphoma,Non-small cell lung cancer

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

TNFRSF10B

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide